Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

183.94 +1.92 (+1.05%)

Streaming Delayed Price Updated: 11:06 AM EDT, Mar 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Jazz Pharmaceuticals' Return On Capital Employed Insights ↗

August 08, 2022

Via Benzinga

'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst ↗

August 05, 2022

Via Benzinga

Where Jazz Pharmaceuticals Stands With Analysts ↗

August 04, 2022

Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings:

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate ↗

May 05, 2022

Via Benzinga

7 Biotech Stocks to Buy for Q3 ↗

July 18, 2022

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

Via InvestorPlace

Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread ↗

July 15, 2022

The company just hired three new executives, likely putting a buyout in the rearview.

Via Investor's Business Daily

Cannabis Stocks Struggle Through Q2 2022 ↗

July 15, 2022

An overview of how cannabis stocks fared in Q2 and what investors should understand about the space.

Via Talk Markets

Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study ↗

July 11, 2022

Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.

Via Benzinga

Brazilian Fund Invests $19M In US Cannabis Stocks ↗

July 05, 2022

As scientific research continues to produce studies on the health benefits of cannabis and CBD and legalization of the plant grows across the globe, not unsurprisingly traditional investment firms are...

Via Benzinga

What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder ↗

June 29, 2022

Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea...

Via Benzinga

Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint ↗

June 28, 2022

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with...

Via Benzinga

Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity ↗

June 28, 2022

Via Benzinga

Switzerland Removes Medical Marijuana Access Limitations As Demand Rises ↗

June 23, 2022

The Swiss government confirmed that it will remove limitations on medical marijuana use, starting August 1st, 2022.

Via Benzinga

This Pharmaceutical Company Is Moving Beyond CBD ↗

June 23, 2022

The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge...

Via Benzinga

Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL ↗

June 23, 2022

Thomas Wesley Pentz, better known for his artistic name, Diplo, partnered with California cannabis beverage company Leisuretown, professional skateboarder Rob Dyrdek and cannabis supply chain company...

Via Benzinga

4 Analysts Have This to Say About Jazz Pharmaceuticals ↗

June 14, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗

June 14, 2022

Upgrades

Via Benzinga

Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research ↗

June 10, 2022

The European Food Safety Authority (EFSA) is asking for more research on the effects of CBD on humans.

Via Benzinga

North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization? ↗

June 09, 2022

The North Carolina House passed Senate Bill 448, legalizing FDA-approved THC medications in a 92-9 vote, reported The Carolina Journal.

Via Benzinga

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study ↗

June 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals ↗

May 27, 2022

The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel...

Via Benzinga

Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028

May 26, 2022

Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...

Via FinancialNewsMedia

Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating ↗

May 17, 2022

Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level.

Via Investor's Business Daily

Jazz Pharmaceuticals's Return On Capital Employed Insights ↗

May 17, 2022

Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between...

Via Benzinga

What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval? ↗

May 11, 2022

Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218.

Via Benzinga

Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next? ↗

May 09, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S.

Via Benzinga

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗

May 05, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY ↗

May 05, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.